Innocoll — Technical Presentation (May 2016)
13 slides from Innocoll's technical presentation, May 25, 2016
Slide 1: XARACOLL Phase 3 Results Webcast
INNOCOlI Engineering Better Medicines XARACOLL Phase 3 Results Webcast MATRIX 1 and MATRIX 2 Clinical Trials May 25, 2016
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements about our ongoing development of XARACOLL and our other product candidates; our interpretation of the data and results from our MATRIX-1 and MATRIX-2 clinical trials; ‘our plans for, and the expected timing of, our XARA
Slide 3: XARACOLL Phase 3 Results
INNOCOlI Engineering Better Medicines XARACOLL Phase 3 Results Tony Zook, Innocoll CEO Lesley Russell, Innocoll CMO MATRIX 1 and MATRIX 2 Clinical Trials May 25, 2016
Slide 4: Innocoll Delivers
Innocoll Delivers Approvable post-op analgesic in the US Differentiated post-op analgesic Efficient in-house manufacturing Collagen platform for sustainable growth High value investment @ Qq «& Qa «& XARACOLL met primary endpoints with highly significant p-values Data and product characteristics for
Slide 5: Delivering on Attractive Growth Outlook
Delivering on Attractive Growth Outlook ° IDE ccllaguard” ini-co3 For Surgical Adhesion Prevention VY Oo iQ® in-002 Results ogenzia inl-002 Pivotal Phase 3 Program ) Phase 3 for Diabetic Foot Infections \) oll? j . Results xaracoll in|-001 Pivotal Phase 3 Program WA Phase 3 for Postoperative Pain wv
Slide 6: MATRIX: Multicenter Assessment of Postoperative Pain Reduction with XARACOLL
MATR IX Multicenter Assessment of PosToperative Pain Reduction wlth XARACOLL Two identical Phase 3, randomized, double-blind, placebo-controlled studies to investigate the efficacy and safety of XARACOLL (bupivacaine-collagen bioresorbable implant, 300 mg) after open laparotomy hernioplasty with mes
Slide 7: XARACOLL MATRIX Phase 3 Program Design
XARACOLL MATRIX Phase 3 Program Design Study Design Allowed Continuous Assessment Study Design for MATRIX 1 & 2 + 300 patients + 300mg dose ‘Treatment Period / Visits Follow-up * Background medication of 650 ma TID wit rescue opioids os needed XARACOLL Matrix ; ; age Primary Endpoint : 2 2 . a ie Ti
Slide 8: Patient Demographics
MATRIX Patient Demographics Top-line summary Patient Demographics and baseline characteristics ° At baseline, treatment groups were well-balanced across both studies for: —age — gender —race —history of previous hernia repair —and surgery duration innocoll
Slide 9: Top-line Efficacy Results
MATRIX Top-line Efficacy Results WA Met the Primary Endpoints (SPI24), the sum of pain intensity "0-24 hrs. ° MATRIX 1 met the primary endpoint (p=0.0004) ° MATRIX 2 met the primary endpoint (p<0.0001) v First long-acting, opioid-sparing, local anesthetic with positive Phase 3 clinical results in he
Slide 10: Secondary Endpoints
MATRIX Secondary Endpoints Pooled data from both trials were statistically significant for SP148, the sum of pain intensity difference 0-48 hrs (p=0.0033) ° MATRIX 2 achieved statistical significance (p=0.0270) ° MATRIX 1 trended toward, but did not achieve statistical significance (j=0.0568) WA Poo
Slide 11: Tolerability and Adverse Event Summary
MATRIX Tolerability and Adverse Event Summary v XARACOLL was well tolerated in both studies WA Incidence of overall adverse events in the XARACOLL arm was \- Ae . . similar to the placebo arm in both studies © There were no XARACOLL-related serious adverse events in either study © Opioid-related adv
Slide 12: Trial Summary and Next Steps
MATRIX Trial Summary and Next Steps Summary Next Steps © XARACOLL met the Primary © NDA preparation and Endpoint in both studies with submission Q3/early Q4 2016 highly significant p-values 2/Analysis ofc] HECONISIUCy ° XARACOLL was safe and well when completed tolerated . . ° Full analysis of the p
Slide 13: Questions
INNSCOll Engineering Better Medicines Questionsé XARACOLL Phase 3 Results Webcast May 25, 2016
Innocoll Holdings — Technical Presentation (May 2016) on 6ix